Posts

Frequently Asked Questions

Learn more about the IFAPP Academy/King’s College London, Medical Affairs in Medicines development, Certification Program

Presented by Dr. Gustavo Kesselring

Want to learn how to expand your skill set and continue your professional development in Medical Affairs?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals.

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course. Click here to learn more about the benefits of Professional Certification from the IFAPP Academy.

The IFAPP Academy welcomes Ana B. Salgado as the new Director of Strategic Planning

Ana B has extensive professional experience in Medical Affairs, Marketing, and senior Business Management. We look forward to her contributions to the sustained growth of the Academy and achieving our mission and goals.

Ana B. Salgado, IFAPP Academy Director of Strategic Planning

Dr. Ana B. Salgado is a highly motivated and energetic pharmaceutical business executive with extensive global experience.

A physician by training, after three years of practicing medicine in the emergency room setting, Dr. Salgado started her pharmaceutical career as Medical Affairs Manager in Roche- Colombia. Her high affinity for change and continuous learning took her career into marketing and the commercial business. She joined Pfizer, where she occupied positions of increasing responsibility in marketing at a country level (Colombia) and later, at regional (Latin America, Europe) and global levels. She worked on products and portfolios across several therapeutic categories including anti-infectives, anti-inflammatories, and neuroscience in collaboration with multi-disciplinary teams around the world. Dr. Salgado was responsible for the launch of Celebrex in Latin America, several neuroscience launches in Europe (Zeldox, Relpax, Lyrica) and she led the Global Team for Aricept (in an alliance collaboration with Eisai – Japan).

Expanding her knowledge into the commercial business, Dr. Salgado served in business operations roles at regional and global level. She became the Chief of Staff for the Established Products/ Emerging Markets Business Unit at Pfizer, a business unit with a $25B yearly turnover. In these roles, Dr. Salgado led and participated in several large and complex corporate initiatives including the mergers of Pfizer with Warner Lambert, Pharmacia and Wyeth; several company reorganizations and the creation of the Established Products Business Unit. Before leaving Pfizer, Dr. Salgado led a global transformation to a customer centric – digitally enabled marketing model.

Dr. Salgado received her medical degree from Pontificia Universidad Javeriana in Colombia. She is currently pursuing a Certificate in Financial Planning.

R&D Costs & Drug Pricing

R&D Costs & Drug Pricing

An article from Kenneth Kaitin, PhD, Professor and Director at Tufts Center for the Study of Drug Development.

This article was originally published by Tufts CSDD Insider.

Kenneth Kaitin, PhD, Professor and Director at Tufts Center for the Study of Drug Development.

Earlier this week, I was interviewed by a National Public Radio affiliate for a segment to be aired in the coming days on whether high drug development costs justify the high prices of many new pharmaceutical products. As many of our readers are aware, Tufts CSDD is known internationally for its series of studies estimating the true cost of pharmaceutical R&D. Our latest study (DiMasi et al, J Health Econ 2016;47:20-33) determined that the fully-capitalized cost to bring a new drug to market, including the cost of failures, is $2.6 billion, a 145% increase in constant dollars over our previous report published in 2003.

At more and more public and professional forums these days, I find myself addressing a common misconception about the relationship between R&D costs and drug prices. Much of this misunderstanding, I believe, comes from confusing messaging by the pharmaceutical industry. For example, when asked to explain why drugs are so expensive, the response is often, because it costs so much to develop new drugs (“The Tufts Center says it costs $2.6 billion to develop a new drug!”). On the other hand, when asked to provide the actual cost data for a specific drug, the response is often, “The cost to develop a drug has no bearing on the price of that drug.” A sane individual might ask, “How can both of these responses be correct?” The bottom line is that they both ARE correct.

As I explain it, average R&D costs represent the cost to maintain R&D operations. In other words, across a company’s marketed drug portfolio, average prices must be high enough for the company to generate sufficient revenue to maintain its R&D operations and (hopefully) develop tomorrow’s breakthrough drug. An individual drug’s price, however, typically reflects that drug’s perceived therapeutic and economic value, the competitive landscape, and the ability to obtain reimbursement. In other words, drug pricing is not unlike pricing of any other product.

The public debate over drug prices and the cost of healthcare in general is certain to continue into the foreseeable future. Greater transparency on how companies determine drug prices and how that relates to R&D costs would go a long way toward improving public understanding and furthering the discussion.

IFAPP Academy Meeting in Budapest

Budapest 2018

In November 2018, the IFAPP Academy was invited by Sandor Kerpel-Fronius to hold the annual face-to-face Steering Committee meeting at the prestigious Semmelweis University in Budapest, Hungary.

Just a few of the Academy’s Board members and operational team

The IFAPP Academy Board Members, stakeholders, IFAPP’s secretariats, and the operations team gathered the first evening in Budapest to share a light dinner, a couple of drinks, and some good conversation.  

The first morning of meetings kicked off with Professor Sandor Kerpel-Fronius, faculty at the Semmelweis University, giving us a history of the University, insider tips to the city, and an overview of the meeting agenda. 

Professor Sandor Kerpel-Fronius inviting us inside the Semmelweis University for our first meeting.

The Academy was excited to welcome Tim Aldwinckle, UCB representative, to the meeting. He was able to provide some great perspective in several areas of the discussion.

After a full day of presentations, the team enjoyed an amazing dinner at Budapest’s Museum Restaurant.

The IFAPP Academy meeting attendees gather for dinner at the Museum Restaurant

Day 2 of the meeting – Gustavo Kesselring and Xavier Luria discussed the strategic collaborations that the IFAPP Academy will be fostering in 2019. Peter Stonier also presented the updated contract with King’s College London. The afternoon was concluded with coffee and the recording of video testimonials starring some of the key representatives of the Academy.

It was a great few days in Budapest and wonderful for the team to be able to spend some quality time together and workout the logistics for a successful 2019 and beyond!

Check out some more of the pictures from the Budapest Steering Committee Meeting:

ICPM 2018 presents the IFAPP Academy, Medical Affairs in Medicines Development, Program Graduates

News from IFAPP Academy

ICPM 2018 presents IFAPP Academy Graduates

What is ICPM?

The International Conference of Pharmaceutical Medicine (ICPM) is the largest event for the International Federation of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP).

ICPM is held every two or three years and is aimed to provide state of the art information in key areas for our discipline and profession. ICPM 2018 was held in Tokyo, September 27th – 29th, (www.icpm2018tokyo.com) in collaboration with the Japanese Association of Pharmaceutical Medicine (http://www.japhmed.org) and brought together around 400 representatives from the pharmaceutical, clinical research, and regulatory arenas from all over the world.


Gustavo Kesselring, MD International Affairs, IFAPP

“Attending the International Conference of Pharmaceutical Medicine (ICPM) is an outstanding opportunity to learn about the news trends in pharmaceutical medicine and medicines development, besides networking with world class faculty from academia, pharmaceutical companies, and government officials in a friendly environment.

Since 2006, in Seoul, I have attended all ICPMs. Being in Tokyo this year, attending the latest ICPM, I am still thrilled about how Pharmaceutical Medicine can motivate people from all parts of the world to get together and discuss the Future of Medicines Development. Hope you don´t miss the ICPMs in the coming years.”


Dr. Marcos O. Perez III receiving his CMD Certificate

Dr. Marcos O. Perez III receiving his CMD Certificate

From left to right: Drs. Gustavo Kesselring, Warachal Eileen Faison (with CMD Certificate), and Honorio Silva

From left to right: Drs. Gustavo Kesselring, Warachal Eileen Faison (with CMD Certificate), and Honorio Silva

Dr. Honorio Silva Introduces the Graduates from the IFAPP Academy Program

Students graduating from the Program were invited to attend ICPM 2018 in Tokyo. Although not all of the students were able to make the trip for the ceremony, Dr Honorio Silva honored each of them through a presentation that included their pictures, job titles, and affiliations.

The students that were able to attend the ceremony were provided free admittance into the conference and presented with their Certificate in Medicines Development (CMD) during the awards ceremony, held the first day of the conference.

Want to learn more about the IFAPP Academy?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals.

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course.

Click here for more information! Applications are now being accepted for the 2019 Cohort. Application deadline is Dec. 1st, 2018

Meet Dr. Sandra Bosold

News from IFAPP Academy


Get to know the students of the IFAPP Academy!

The IFAPP Academy is proud to highlight the achievements and successes of our current students and alumni.

We would like to introduce you to, Dr. Sandra Bosold, a current student of the IFAPP Academy/King’s College London, Medical Affairs in Medicines Development, Certification Program.

IFAPP Academy featured student: Dr. Sandra Bosold

What is your name and job title?

Dr. Sandra Bosold, Scientific Advisor PIH

What do you feel is your greatest achievement?

One daily achievement is to manage my job responsibilities and the activities and needs of my family. Due to the flexibility of my employer and the appropriate infrastructure, it is possible to balance both.

What is your favorite hobby and/or activity outside of your work?

Gardening and family.

What do you enjoy most about being a Medical Affairs Professional?

Working as a MAP you are at the interface between the medical/scientific world and the interests of a company. Scientific exchanges with HCPs, participation in conferences, and discussions with patients are at the center of our activities and make this job incredibly interesting.

What has been the most beneficial aspect of the IFAPP Academy Program?

Besides the well-structured and detailed lectures, the live webinars with the opportunity to discuss certain issues with top experts but also with the IFAPP colleagues are extremely valuable.

How has your view of the medical affairs profession altered and/or improved?

While going through the curriculum it became clear that Medical Affairs is at the center of all activities and cannot be underestimated. The discussions with KOLs, the insights into patients’ journeys, the scientific knowledge and the cooperation with academia are the foundation of our business.

Any additional comments that you would like to make about the Program?

I have greatly benefitted from the exchange with colleagues from all over the world. IFAPP’s program is a truly global one.

Thank you, Sandra! The Academy looks forward to seeing your many great achievements and contributions to the Medical Affairs arena.

Want to learn more about the IFAPP Academy?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals.

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course. Applications are now being accepted for the 2019 Cohort. Click here for more information. Application deadline is December 1st, 2018.

The Shared Ethical Responsibility of Medically and Non-medically Qualified Experts in Human Drug Development Teams